Shares of AxoGen, Inc (NASDAQ:AXGN) have earned an average rating of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $33.14.
Several brokerages have commented on AXGN. Jefferies Group boosted their price target on shares of AxoGen to $45.00 and gave the stock a “buy” rating in a research report on Monday, March 19th. Lake Street Capital set a $38.00 target price on shares of AxoGen and gave the company a “buy” rating in a report on Friday, March 2nd. JMP Securities upped their target price on shares of AxoGen from $27.00 to $34.00 and gave the company a “market outperform” rating in a report on Thursday, March 1st. BidaskClub raised shares of AxoGen from a “buy” rating to a “strong-buy” rating in a report on Friday, February 23rd. Finally, William Blair began coverage on shares of AxoGen in a report on Monday, February 5th. They issued an “outperform” rating on the stock.
In other news, CFO Jamie Mark Grooms sold 95,712 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $26.84, for a total value of $2,568,910.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 169,407 shares of company stock worth $4,593,013. 9.33% of the stock is owned by insiders.
NASDAQ:AXGN traded down $0.70 on Friday, hitting $37.00. 338,790 shares of the company’s stock were exchanged, compared to its average volume of 412,063. The company has a debt-to-equity ratio of 0.79, a current ratio of 4.07 and a quick ratio of 3.53. AxoGen has a 52 week low of $10.35 and a 52 week high of $40.95. The stock has a market capitalization of $1,278.72, a PE ratio of -119.35 and a beta of 0.01.
AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The firm had revenue of $16.97 million for the quarter, compared to analysts’ expectations of $16.38 million. During the same period in the previous year, the firm posted ($0.10) EPS. The company’s revenue for the quarter was up 48.7% on a year-over-year basis. analysts anticipate that AxoGen will post -0.3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3341889/axogen-inc-axgn-receives-consensus-rating-of-buy-from-analysts.html.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.